- Home
- GORV vs APRE Comparison
GORV vs APRE Comparison
Compare GORV & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- APRE
- Stock Information
- Founded
- GORV 1976
- APRE 2006
- Country
- GORV United States
- APRE United States
- Employees
- GORV N/A
- APRE N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GORV Consumer Discretionary
- APRE Health Care
- Exchange
- GORV Nasdaq
- APRE Nasdaq
- Market Cap
- GORV 9.3M
- APRE 8.3M
- IPO Year
- GORV 2015
- APRE 2019
- Fundamental
- Price
- GORV $2.36
- APRE $1.56
- Analyst Decision
- GORV
- APRE Strong Buy
- Analyst Count
- GORV 0
- APRE 1
- Target Price
- GORV N/A
- APRE $20.00
- AVG Volume (30 Days)
- GORV 1.6M
- APRE 105.1K
- Earning Date
- GORV 11-17-2025
- APRE 11-06-2025
- Dividend Yield
- GORV N/A
- APRE N/A
- EPS Growth
- GORV N/A
- APRE N/A
- EPS
- GORV N/A
- APRE N/A
- Revenue
- GORV $662,952,000.00
- APRE $841,012.00
- Revenue This Year
- GORV $15.65
- APRE N/A
- Revenue Next Year
- GORV $20.54
- APRE N/A
- P/E Ratio
- GORV N/A
- APRE N/A
- Revenue Growth
- GORV N/A
- APRE N/A
- 52 Week Low
- GORV $1.83
- APRE $1.37
- 52 Week High
- GORV $58.80
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- GORV 46.71
- APRE 55.50
- Support Level
- GORV $1.96
- APRE $1.40
- Resistance Level
- GORV $2.35
- APRE $1.69
- Average True Range (ATR)
- GORV 0.34
- APRE 0.09
- MACD
- GORV 0.03
- APRE 0.02
- Stochastic Oscillator
- GORV 39.32
- APRE 62.71
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.